Pharmacology of zolimidine (2-(p-methylsulfonylphenyl)-imidazo (1,2-a) pyridine) a new non-anticholinergic gastroprotective agent. IV) Enhancement of gastric mucus production in different experimental models.
D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001241:Aspirin; D003080:Cold Temperature; D005752:Gastric Mucins / Q000096:biosynthesis*; D005753:Gastric Mucosa / Q000187:drug effects; D006168:Guinea Pigs; D006632:Histamine; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology*; D007103:Immobilization; D007213:Indomethacin; D010276:Parasympatholytics / Q000494:pharmacology*; D010437:Peptic Ulcer / Q000517:prevention & control; D010653:Phenylbutazone; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D013270:Stomach / Q000187:drug effects; D013276:Stomach Ulcer / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control; D013312:Stress, Physiological / Q000150:complications
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D005752:Gastric Mucins; D006634:Histamine H1 Antagonists; D007093:Imidazoles; D010276:Parasympatholytics; D011725:Pyridines; D006632:Histamine; D010653:Phenylbutazone; D001241:Aspirin; D007213:Indomethacin